Clinical study of aspirin batroxobin combined with low-molecular-weight heparin in patients with acute cerebral infarction

Objective: To investigate the therapeutic efficacy of aspirin,batroxobin combined with low-molecular-weight heparin on the acute cerebral infarction and to evaluate the safety of the three drugs. Methods: 101 cases with acute cerebral infarction were randomly devided into two groups:(1)50 cases were treated with batroxobin,low-molecular-weight heparin combined with aspirin;(2)51 cases were given batroxobin and aspirin. Blood viscosity was estimated before and after treatment. The scores of NIHSS,Barthel were estimated before and 15 and 30 and 90 days after treatment. Results: In these two groups ,plasma fibrinogen,high shear rate and hematocrit were decreased after the therapy(P0.05).The decreases of high shear rate and hematocrit were more improved in aspirin ,batroxobin combined with low-molecular-weight heparin therapy group than those in aspirin plus batroxobin therapy group.The significant statistical difference was found(P0.05). 90 days after the therapy.The scores of NIHSS,Barthel were more improved in aspirin,batroxobin combined with low-molecular-weight heparin therapy group than those in aspirin plus batroxobin therapy group.The significant statistical difference was found (P0.05). There was no statistical difference in systemic hemorrhage in those two groups.Conclusion: Aspirin,batroxobin combined with low-molecular-weight heparin therapy may be beneficial to restoring the nervous function. It can improve the prognosis and be safety.